Dr. Reddy’s will manufacture Prurisol for oral dosing at levels sufficient for the Cellceutix’s planned Phase 2/3 clinical trials, which are scheduled to begin upon completion of the manufacturing.
Cellceutix chief executive officer Leo Ehrlich said that the research showed Prurisol to be effective than methotrexate, a standard of care treatment for advanced psoriasis, as there was no recurrence of psoriasis on the animals. Visually, it eliminated all indications of psoriasis.
"Dr. Reddy’s is a perfect fit for Prurisol. Prurisol has a complex process for synthesizing and manufacturing in oral form and we are very pleased to have Dr. Reddy’s handling those formulations," Ehrlich added.
The Phase 2/3 clinical trials are at present in meetings with clinical sites in Europe and the US.